Threadgill Financial LLC Has $354,000 Position in Eli Lilly and Company (NYSE:LLY)

Threadgill Financial LLC cut its stake in Eli Lilly and Company (NYSE:LLY) by 63.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 400 shares of the company’s stock after selling 700 shares during the period. Threadgill Financial LLC’s holdings in Eli Lilly and Company were worth $354,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Regal Investment Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 41.3% during the 4th quarter. Regal Investment Advisors LLC now owns 4,808 shares of the company’s stock worth $2,803,000 after acquiring an additional 1,405 shares during the period. VitalStone Financial LLC boosted its holdings in shares of Eli Lilly and Company by 35.5% in the 4th quarter. VitalStone Financial LLC now owns 1,249 shares of the company’s stock valued at $728,000 after purchasing an additional 327 shares in the last quarter. Advanced Portfolio Management LLC bought a new position in shares of Eli Lilly and Company in the 4th quarter valued at $1,736,000. Visionary Wealth Advisors lifted its position in shares of Eli Lilly and Company by 2.7% during the 4th quarter. Visionary Wealth Advisors now owns 1,872 shares of the company’s stock worth $1,091,000 after buying an additional 49 shares during the last quarter. Finally, Bridgewater Associates LP boosted its stake in Eli Lilly and Company by 412.5% in the fourth quarter. Bridgewater Associates LP now owns 317,586 shares of the company’s stock valued at $185,127,000 after buying an additional 255,619 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research reports. Truist Financial reissued a “buy” rating and issued a $1,000.00 target price (up previously from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Citigroup initiated coverage on shares of Eli Lilly and Company in a research report on Friday, September 13th. They issued a “buy” rating and a $1,060.00 target price on the stock. Bank of America upped their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Guggenheim raised their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Finally, Jefferies Financial Group upped their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $977.35.

Eli Lilly and Company Price Performance

Shares of LLY opened at $898.40 on Tuesday. The business’s fifty day moving average is $900.13 and its 200 day moving average is $848.40. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The stock has a market cap of $853.84 billion, a P/E ratio of 132.31, a P/E/G ratio of 2.78 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Sell-side analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the transaction, the insider now directly owns 96,943,810 shares of the company’s stock, valued at approximately $91,109,731,514.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.